This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Upside Options Flow in Bristol-Myers

 
 
By David Russell of OptionMonster
 
NEW YORK -- Pharmaceuticals were strong on Friday, and upside options were really flowing in Bristol-Myers Squibb (BMY).
 
OptionMonster's tracking systems detected bullish activity at two strikes in particular. Traders started with the shorter-term Weekly 54 calls expiring on Dec. 6, snapping up more than 5,000 contracts in volume well above previous open interest of 1,316. Premiums rose from 22 cents to 41 cents, with most of the large blocks pricing for 24 cents to 34 cents. .
 
These long calls lock in the price where a stock can be purchased, letting investors profit from a rally while risking only small amounts of capital. Their cheap cost also offers the potential for significant leverage if the drug maker pushes higher.
 
About an hour later, buyers turned to the March 52.50 calls, mostly paying $2.92. Some 5,400 changed hands against open interest of 1,047 contracts.
 
Bristol-Myers ended the session up 2.02% to $53.41. The company received a key upgrade from Morgan Stanley on Oct. 28 based on the promise of its cancer treatments. Shares have been consolidating at their highest levels in more than a decade since then.
 
Total option volume in the name was four times greater than average in the session. Overall calls outnumbered puts by almost 5 to 1.
 
Russell has no positions in BMY.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $130.79 -0.75%
FB $79.20 -1.20%
GOOG $533.00 -1.30%
TSLA $250.10 -0.54%
YHOO $42.99 -0.19%

Markets

DOW 18,037.74 -88.38 -0.49%
S&P 500 2,114.32 -6.47 -0.31%
NASDAQ 5,088.5380 -9.4380 -0.19%

Partners Compare Online Brokers

Free Reports